DelveInsight Releases Narcolepsy Drug Pipeline Report for 2026

DelveInsight, a healthcare research firm, has published its "Narcolepsy Pipeline Insight, 2026" report, providing a comprehensive overview of the global drug development landscape for narcolepsy.

The report details the progress of more than 12 companies and 15 drugs currently in various stages of development, from preclinical to clinical trials. It analyzes pipeline assets by product type, development stage, route of administration, and molecule type, also identifying discontinued or inactive projects.

Narcolepsy is a chronic neurological disorder affecting the brain's ability to regulate sleep-wake cycles, characterized by excessive daytime sleepiness and sudden sleep attacks, sometimes accompanied by cataplexy. While the exact cause remains unknown, research points to autoimmune factors and genetic predisposition, particularly in Type 1 narcolepsy linked to hypocretin deficiency.

Current treatments focus on managing symptoms through medication and lifestyle adjustments. The pipeline report highlights new therapeutic candidates aiming to improve wakefulness, sleep quality, and address underlying disease mechanisms. This report offers updated intelligence on ongoing research and development efforts in the narcolepsy space.